Trial reportNature metabolism2025
Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19.
Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Nature metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07156929 (Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation: CICR-NAM as Food for Special Medicinal Purposes (FSMP)
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Domain-specific effects of NADFrontiers in nutrition · 2026Pooled it
- Tracing NADCell reports · 2026Article
- NADThe Journal of general virology · 2026Review
- Nicotinamide attenuates the virulence of colorectal cancer-associatedInfection and immunity · 2026Article
- A metabolic constraint in de novo NAD+ synthesis drives mucosal inflammation in IBD.Journal of Crohn's & colitis · 2026Article
- Tryptophan pathway metabotypes associate with disease activity and immune-metabolic dysfunction in inflammatory bowel disease.medRxiv : the preprint server for health sciences · 2026Article
- Therapeutic potential of dihydronicotinamide riboside (NRH) on obesity and glucose intolerance in mice.Nature communications · 2026Article
- Role and Mechanisms of Gut Microbiota in Infectious Diseases: Recent Evidence from Animal Models.Biology · 2026Review
- NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations.JCI insight · 2026Article
- Systematic Screening of Tryptophan Metabolism Identifies Site- and Microbiota-Dependent Signatures of Tryptophan Utilization in Experimental Colitis.International journal of tryptophan research : IJTR · 2026Article
- Tracing NADResearch square · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Stefan Schreiber *Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany. s.schreiber@mucosa.de.ORCID http://orcid.org/0000-0003-2254-7771
Georg H Waetzig *Institute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany.
Víctor A López-AgudeloInstitute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany.
Corinna GeislerInstitute of Diabetes and Clinical Metabolic Research, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany.
Kristina SchlichtInstitute of Diabetes and Clinical Metabolic Research, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0003-0281-5142
Sina FranzenburgCompetence Network Intestinal Diseases, Kiel, Germany.
Romina di GiuseppeCompetence Network Intestinal Diseases, Kiel, Germany.
Daniel PapeDepartment of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
Thomas BahmerDepartment of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
Michael KrawczakInstitute of Medical Informatics and Statistics, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany.
Elisabeth KokottDepartment of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
Josef M PenningerHelmholtz Centre for Infection Research, Braunschweig, Germany.ORCID http://orcid.org/0000-0002-8194-3777
Oliver HarzerBioscientia Healthcare GmbH, Ingelheim, Germany.
Jan KramerLADR Laboratory Group Dr. Kramer & Colleagues, Geesthacht, Germany.
Tammo von SchrenckLabor Dr. von Froreich, Hamburg, Germany.
Felix SommerInstitute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0002-6545-3487
Helena U ZachariasPeter L. Reichertz Institute for Medical Informatics of TU Braunschweig and Hannover Medical School, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0003-3633-1330
COVit-2 Study Group
Belén Millet Pascual-LeoneDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité-Universitätsmedizin Berlin, a corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-4287-282X
Sofia K ForslundExperimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-4285-6993
Jan HeyckendorfDepartment of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
Konrad AdenDepartment of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0003-3482-7316
Regina HollweckNovustat GmbH, Wollerau, Switzerland.
Matthias LaudesDepartment of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0002-7846-955X
Philip RosenstielInstitute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Kiel, Germany.ORCID http://orcid.org/0000-0002-9692-8828
Funding
Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) e:Med CKDNapp 01ZX1912ABundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) e:Med Juniorverbund "Try-IBD" 01ZX1915A and 01ZX2215, e:Med Network iTREAT 01ZX2202AChristian-Albrechts-Universität zu Kiel (Christian-Albrechts-University Kiel) K126408Deutsche Forschungsgemeinschaft (German Research Foundation) EXC 2167Deutsche Forschungsgemeinschaft (German Research Foundation) EXC 2167: CD-1, CD-2, TI-1Deutsche Forschungsgemeinschaft (German Research Foundation) EXC 2167: CD-2, RTF-VI, TI-1Deutsche Forschungsgemeinschaft (German Research Foundation) EXC 2167: RTF-VIDeutsche Forschungsgemeinschaft (German Research Foundation) miTARGET (RU5042)Deutsche Forschungsgemeinschaft (German Research Foundation) SFB1470, SFB1449Deutsche Forschungsgemeinschaft (German Research Foundation) SO1141/10-1
Abstract
Cellular NAD
Indexed as
COVID-19COVID-19 Drug TreatmentGastrointestinal MicrobiomeNiacinamideAdultAgedDouble-Blind MethodDysbiosisFecesFemaleHumansMaleMiddle AgedProspective StudiesSARS-CoV-2TryptophanNiacinamideTryptophan
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT07156929ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.